Verona Pharma plc (VRNA)
NASDAQ: VRNA · IEX Real-Time Price · USD
15.46
-0.05 (-0.32%)
At close: Jul 2, 2024, 4:00 PM
15.45
-0.01 (-0.06%)
After-hours: Jul 2, 2024, 7:20 PM EDT
Verona Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Verona Pharma stock have an average target of 35, with a low estimate of 33 and a high estimate of 36. The average target predicts an increase of 126.39% from the current stock price of 15.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $35 | Strong Buy | Maintains | $35 | +126.39% | Jun 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $32 → $36 | Strong Buy | Maintains | $32 → $36 | +132.86% | Jun 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $33 → $30 | Strong Buy | Maintains | $33 → $30 | +94.05% | May 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $31 → $36 | Buy | Maintains | $31 → $36 | +132.86% | Apr 16, 2024 |
Financial Forecast
Revenue This Year
8.71M
Revenue Next Year
92.30M
from 8.71M
Increased by 960.17%
EPS This Year
-1.60
from -0.72
EPS Next Year
-1.15
from -1.60
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.0M | 176.9M | 500.4M | 1.2B | 2.4B |
| Avg | 8.7M | 92.3M | 319.6M | 595.9M | 1.3B |
| Low | 2.2M | 35.8M | 199.5M | 391.6M | 716.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,931.7% | 442.1% | 259.8% | 300.3% |
| Avg | - | 960.2% | 246.3% | 86.4% | 115.3% |
| Low | - | 311.2% | 116.2% | 22.5% | 20.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.61 | -0.64 | -0.14 | 1.22 | 3.38 |
| Avg | -1.60 | -1.15 | -0.38 | 0.67 | 2.00 |
| Low | -1.63 | -1.62 | -0.61 | 0.22 | 0.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 406.1% |
| Avg | - | - | - | - | 198.7% |
| Low | - | - | - | - | 12.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.